Editas Medicine, Inc. (NASDAQ:EDIT) CFO Andrew A. F. Hack sold 5,000 shares of Editas Medicine stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $25.35, for a total value of $126,750.00. Following the transaction, the chief financial officer now directly owns 5,000 shares in the company, valued at approximately $126,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Editas Medicine, Inc. (NASDAQ EDIT) traded up $0.41 during mid-day trading on Tuesday, hitting $25.46. The company’s stock had a trading volume of 572,800 shares, compared to its average volume of 914,436. Editas Medicine, Inc. has a one year low of $13.12 and a one year high of $29.20. The company has a current ratio of 10.12, a quick ratio of 10.12 and a debt-to-equity ratio of 0.19.

Editas Medicine (NASDAQ:EDIT) last announced its earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Editas Medicine had a negative net margin of 1,127.03% and a negative return on equity of 70.19%. The company had revenue of $6.28 million during the quarter, compared to analysts’ expectations of $2.66 million. During the same quarter last year, the business posted ($0.59) earnings per share. The company’s revenue for the quarter was up 553.0% compared to the same quarter last year. equities analysts expect that Editas Medicine, Inc. will post -2.92 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Editas Medicine, Inc. (EDIT) CFO Sells 5,000 Shares of Stock” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/21/insider-selling-editas-medicine-inc-edit-cfo-sells-5000-shares-of-stock.html.

Several institutional investors have recently bought and sold shares of EDIT. Vanguard Group Inc. boosted its stake in shares of Editas Medicine by 47.0% in the first quarter. Vanguard Group Inc. now owns 1,935,173 shares of the company’s stock valued at $43,193,000 after buying an additional 618,789 shares in the last quarter. State Street Corp boosted its stake in shares of Editas Medicine by 305.4% in the second quarter. State Street Corp now owns 537,640 shares of the company’s stock valued at $9,022,000 after buying an additional 405,022 shares in the last quarter. American Century Companies Inc. purchased a new stake in shares of Editas Medicine in the third quarter valued at approximately $7,497,000. Ark Investment Management LLC boosted its stake in shares of Editas Medicine by 121.9% in the second quarter. Ark Investment Management LLC now owns 510,187 shares of the company’s stock valued at $8,561,000 after buying an additional 280,265 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Editas Medicine by 245.9% in the second quarter. Northern Trust Corp now owns 373,149 shares of the company’s stock valued at $6,261,000 after buying an additional 265,273 shares in the last quarter. Hedge funds and other institutional investors own 69.35% of the company’s stock.

Several research analysts have commented on EDIT shares. ValuEngine lowered Editas Medicine from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. Zacks Investment Research lowered Editas Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Cann reaffirmed a “hold” rating on shares of Editas Medicine in a research report on Tuesday, November 7th. J P Morgan Chase & Co set a $27.00 price target on Editas Medicine and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $28.00 target price (up from $27.00) on shares of Editas Medicine in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, six have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $26.73.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Insider Buying and Selling by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.